CAMBRIDGE, Mass., March 13, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for
the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest
company overview at the 17th Annual Needham Healthcare Conference in New York, New York on Wednesday, March 28, 2018 at
9:00am Eastern Time.
The presentation will be live webcast at: http://wsw.com/webcast/needham86/vcel, and may be accessed from the news and events
section of the Vericel website.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell
therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an
autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage
defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent
skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body
surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights
reserved.
(vcel-corp)
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
David.schull@russopartnersllc.com
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
Karen.chase@russopartnersllc.com
Investor Contacts:
Chad Rubin
The Trout Group
crubin@troutgroup.com
+1 (646) 378-2947
Lee Stern
The Trout Group
lstern@troutgroup.com
+1 (646) 378-2922
